14-DeoxyandrographolideCAS# 4176-97-0 |
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 4176-97-0 | SDF | Download SDF |
| PubChem ID | 11624161 | Appearance | White powder |
| Formula | C20H30O4 | M.Wt | 334.45 |
| Type of Compound | Diterpenoids | Storage | Desiccate at -20°C |
| Solubility | Soluble in acetonitrile and chloroform | ||
| Chemical Name | 4-[2-[(1R,4aS,5R,6R,8aS)-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylidene-3,4,4a,6,7,8-hexahydro-1H-naphthalen-1-yl]ethyl]-2H-furan-5-one | ||
| SMILES | CC12CCC(C(C1CCC(=C)C2CCC3=CCOC3=O)(C)CO)O | ||
| Standard InChIKey | GVRNTWSGBWPJGS-YSDSKTICSA-N | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | 1. 14-Deoxyandrographolide desensitizes hepatocytes to TNF-alpha-mediated apoptosis through the release of TNFRSF1A. 2. 14-Deoxyandrographolide has hepatoprotective activity, mediates activation of adenylate cyclase-cAMP signaling leading to up-regulation of cNOS, may provide a promising approach in the prevention of liver diseases during chronic alcoholism. |
| Targets | AMPK | NOS | cAMP | TNF-α | ATPase | Calcium Channel |
14-Deoxyandrographolide Dilution Calculator
14-Deoxyandrographolide Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.99 mL | 14.9499 mL | 29.8998 mL | 59.7997 mL | 74.7496 mL |
| 5 mM | 0.598 mL | 2.99 mL | 5.98 mL | 11.9599 mL | 14.9499 mL |
| 10 mM | 0.299 mL | 1.495 mL | 2.99 mL | 5.98 mL | 7.475 mL |
| 50 mM | 0.0598 mL | 0.299 mL | 0.598 mL | 1.196 mL | 1.495 mL |
| 100 mM | 0.0299 mL | 0.1495 mL | 0.299 mL | 0.598 mL | 0.7475 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- ar-Curcumene
Catalog No.:BCN7534
CAS No.:4176-06-1
- Evonimine
Catalog No.:BCN3082
CAS No.:41758-69-4
- Dihydrophaseic acid
Catalog No.:BCN5478
CAS No.:41756-77-8
- Ophiopogonin D
Catalog No.:BCN5004
CAS No.:41753-55-3
- Ginsenoside Rb1
Catalog No.:BCN1063
CAS No.:41753-43-9
- Acuminatin
Catalog No.:BCN5477
CAS No.:41744-39-2
- (-)-Sativan
Catalog No.:BCN7752
CAS No.:41743-86-6
- Irisflorentin
Catalog No.:BCN1278
CAS No.:41743-73-1
- Pyrochamissanthin
Catalog No.:BCN3612
CAS No.:41743-60-6
- Sugeroside
Catalog No.:BCN6961
CAS No.:41743-57-1
- Luteone
Catalog No.:BCN5476
CAS No.:41743-56-0
- Procyanidin A2
Catalog No.:BCN6805
CAS No.:41743-41-3
- Lenvatinib (E7080)
Catalog No.:BCC1172
CAS No.:417716-92-8
- H-Leu-pNA.HCl
Catalog No.:BCC2972
CAS No.:4178-93-2
- Hypecorinine
Catalog No.:BCN3298
CAS No.:41787-57-9
- Junicedric acid
Catalog No.:BCN7660
CAS No.:41787-69-3
- Hesperetin-7-methyl ether
Catalog No.:BCN8501
CAS No.:
- Mangiferolic acid
Catalog No.:BCN4636
CAS No.:4184-34-3
- Alatamine
Catalog No.:BCN3100
CAS No.:41855-33-8
- Bezafibrate
Catalog No.:BCC4639
CAS No.:41859-67-0
- 2,3-DCPE hydrochloride
Catalog No.:BCC2384
CAS No.:418788-90-6
- PYR-41
Catalog No.:BCC4470
CAS No.:418805-02-4
- Nitrocefin
Catalog No.:BCC6544
CAS No.:41906-86-9
- Isopropyl 4-Hydroxybenzoate
Catalog No.:BCN8409
CAS No.:4191-73-5
14-Deoxyandrographolide alleviates ethanol-induced hepatosteatosis through stimulation of AMP-activated protein kinase activity in rats.[Pubmed:24507479]
Alcohol. 2014 Mar;48(2):123-32.
Andrographis paniculata (AP) is a traditional medicinal plant of Ayurveda. It grows widely in Asia and is prescribed in the treatment of liver diseases. Here we have investigated the beneficial role of 14-Deoxyandrographolide (14-DAG), a bioactive diterpenoid from AP, against alcoholic steatosis in rats. 14-DAG was extracted from aerial parts (leaves and stems) of AP. Rats were fed with ethanol for 8 weeks. Animals were treated with 14-DAG during the last 4 weeks of ethanol treatment. In vitro studies were undertaken in a human hepatocellular liver carcinoma cell line culture. Hepatosteatosis was assessed from histopathological studies of liver sections. Acetyl-CoA, malonyl-CoA, and triglyceride contents were determined using commercially available kits. Fatty acid synthesis was evaluated from incorporation of 1-(14)C acetate. Regulation of fatty acid oxidation and lipogenesis were monitored with immunoblotting and immunoprecipitation studies. Ethanol exposure led to hepatotoxicity, as evident from the marked enhancement in the levels of AST and ALT. The values decreased almost to control levels in response to 14-DAG treatment. Results showed that ethanol feeding induced deactivation of AMP-activated protein kinase (AMPK) that led to enhanced lipid synthesis and decreased fatty acid oxidation, culminating in hepatic fat accumulation. Treatment with 14-DAG activated AMPK through induction of cyclic AMP-protein kinase A pathway. Activation of AMPK was followed by down-regulation of sterol regulatory element binding protein-1c, acetyl-CoA carboxylase, and fatty acid synthase, leading to suppression of lipogenesis. This was associated with up-regulation of sirtuin 1 and depletion of malonyl-CoA, in favor of increased fatty acid oxidation. 14-DAG controlled ethanol-induced hepatosteatosis by interfering with dysregulation of lipid metabolism. In conclusion, our results indicated that 14-DAG was capable of preventing the development of fatty liver through AMPK-mediated regulation of lipid metabolism. This finding supported the hepatoprotective role of 14-DAG, which might serve as a therapeutic option to alleviate hepatosteatosis in chronic alcoholism.
14-Deoxyandrographolide desensitizes hepatocytes to tumour necrosis factor-alpha-induced apoptosis through calcium-dependent tumour necrosis factor receptor superfamily member 1A release via the NO/cGMP pathway.[Pubmed:20649583]
Br J Pharmacol. 2010 Aug;160(7):1823-43.
BACKGROUND AND PURPOSE: Andrographis paniculata (AP) has been found to display hepatoprotective effect, although the mechanism of action of the active compounds of AP in this context still remains unclear. Here, we evaluated the hepatoprotective efficacy of 14-Deoxyandrographolide (14-DAG), a bioactive compound of AP, particularly its role in desensitization of hepatocytes to tumour necrosis factor-alpha (TNF-alpha)-induced signalling of apoptosis. EXPERIMENTAL APPROACH: TNF-alpha-mediated ligand receptor interaction in hepatocytes in the presence of 14-DAG was studied in vitro in primary hepatocyte cultures, with the help of co-immunoprecipitation, confocal microscopy and FACS analysis. Events associated with 14-DAG-induced TNFRSF1A release from hepatocytes were determined using immunoblotting, biochemical assay and fluorimetric studies. Pulse-chase experiments with radiolabelled TNF-alpha and detection of apoptotic nuclei by terminal transferase-mediated dUTP nick-end labelling were performed under in vivo conditions. KEY RESULTS: 14-DAG down-regulated the formation of death-inducing signalling complex, resulting in desensitization of hepatocytes to TNF-alpha-induced apoptosis. Pretreatment of hepatocytes with 14-DAG accentuated microsomal Ca-ATPase activity through induction of NO/cGMP pathway. This resulted in enhanced calcium influx into microsomal lumen with the formation of TNFRSF1A-ARTS-1-NUCB2 complex in cellular vesicles. It was followed by the release of full-length 55 kDa TNFRSF1A and a reduction in the number of cell surface TNFRSF1A, which eventually caused diminution of TNF-alpha signal in hepatocytes. CONCLUSION AND IMPLICATION: Taken together, the results demonstrate for the first time that 14-DAG desensitizes hepatocytes to TNF-alpha-mediated apoptosis through the release of TNFRSF1A. This can be used as a strategy against cytokine-mediated hepatocyte apoptosis in liver dysfunctions.
14-Deoxyandrographolide targets adenylate cyclase and prevents ethanol-induced liver injury through constitutive NOS dependent reduced redox signaling in rats.[Pubmed:23764359]
Food Chem Toxicol. 2013 Sep;59:236-48.
Chronic alcoholism is one of the most common causes of liver diseases worldwide. Nitric oxide (NO) has been proposed to have potential for clinical application against chronic hepatocellular injuries. However, mechanisms underlying hepatoprotective functions of NO in ethanol-induced apoptosis are largely unknown. Sprauge-Dawley rats were exposed to ethanol for 8 weeks. Half of the ethanol-fed animals received 14-Deoxyandrographolide (14-DAG) treatment for the last 4 weeks of study. Preventive effect of 14-DAG against ethanol-induced hepatotoxicity involved constitutive nitric oxide synthase (cNOS) activation followed by up-regulation of gamma-glutamylcysteine synthetase activity and reduced oxidative stress. Enhanced interaction of cNOS with caveolin-1 caused down-regulation of enzyme activity and led to depletion of NO in the hepatocytes of ethanol-fed animals. 14-DAG acted as activator of adenylate cyclase and modulated cyclic AMP (cAMP) mediated expression of caveolin-1 and calmodulin. This eventually favored activation of cNOS through inhibition of cNOS-caveolin-1 interaction. Our results suggest that, protective effect of 14-DAG against ethanol-induced hepatic injury is based on its ability to reduce oxidative stress through cNOS dependent improvement of redox status. 14-DAG mediated activation of adenylate cyclase-cAMP signaling leading to up-regulation of cNOS may provide a promising approach in the prevention of liver diseases during chronic alcoholism.
